Longitude Capital
Menlo Park · Series A–Late Stage · 25 people tracked
Investment thesis
Longitude Capital pursues venture growth investments in life sciences companies with clinically de-risked assets, favorable valuations relative to risk profile, and expected returns within three to five years. The firm identifies opportunities through its broad industry network and proprietary thematic research into emerging therapeutic areas. It employs diverse investment structures including traditional venture capital, spin-outs, recapitalizations, PIPEs, open market purchases, and equity-linked instruments. Post-investment, the team collaborates closely with portfolio companies on strategic planning, team building, capital raising, and liquidity optimization.
Source: firm website, verified Jul 20, 2026.
Team · 25 people
from the firm's websiteManaging Director and Founder with significant life sciences operations experience including senior executive positions at Valentis, Hoffman-La Roche, and Novartis. Previously co-led life sciences investments at Pequot Ventures and worked in venture capital at PaineWebber Development Corporation.
Managing Director and Founder with over 200 years combined team investing experience. Previously founded the life sciences practice at Pequot Ventures and held executive roles at Waste Management International, Banque Paribas, and PaineWebber. Serves on boards of multiple public and private healthcare companies.
Managing Director who joined in 2018 after serving as an Engagement Manager in McKinsey's pharmaceuticals and medical products practice. Holds an MD from Stanford School of Medicine and BS in Biomedical Engineering from Johns Hopkins University.
Managing Director who joined in 2016 with experience in strategy, finance, and operations at Cardinal Health, where he helped deploy over $6 billion in capital through M&A and minority investments. Also held marketing leadership roles in cardiovascular device franchises.
Managing Director who joined in 2022 from GRAIL, where he served as Chief Operating Officer and CFO. Previously held senior finance roles at Jazz Pharmaceuticals, a Longitude portfolio company, and worked as an investment banker for nearly 20 years advising life sciences companies.
Managing Director and CFO responsible for financial reporting, firm-wide finance, tax, human resources, IT, and administration. Served as Chief Compliance Officer from 2014 to 2021. Joined in 2008 with prior experience as Controller at Sierra Ventures and positions at NetManage and Arthur Andersen.
Principal who joined full-time in 2022 after serving as a Longitude Research Fellow. Published research in leading journals including Nature Biotechnology and Cancer Cell. Earned a PhD in Biology from MIT specializing in gene editing and cancer immunology.
Vice President who joined in 2025 after completing fellowships with healthcare investment firms including Foresite Capital and Insight Partners. Published work in leading journals on biotechnology topics. Holds an MD from UCSF and PhD in Biological and Biomedical Sciences from Harvard Medical School.
Venture Partner who joined in 2025 after co-founding Seven Fleet Capital and working at Walleye Capital covering publicly listed pharmaceutical and biotechnology companies. Previously served in roles at the FDA and Hatteras Venture Partners. Holds a PhD in Pharmaceutical Sciences from UNC Chapel Hill.
Venture Partner who joined in 2023 with more than 25 years in clinical drug development and medical affairs. Previously Chief Medical Officer at Surrozen and Vice President of Medical Affairs at Jazz Pharmaceuticals, a Longitude portfolio company. Holds MD and PhD from Catholic University in Leuven.
Venture Partner and Founder with experience in life sciences management consulting and investment roles at Pequot Ventures, J.P. Morgan, and Vector Fund Management. Holds an MBA in Finance and Health Services Management from Kellogg School of Management.
Head of Legal and Chief Compliance Officer who joined in 2020 from Weil, Gotshal & Manges, where she was a Senior Associate counseling companies and funds on M&A, securities law, venture financings, and commercial arrangements. Holds a JD from UC Berkeley School of Law.
Vice President of People who joined in 2025 from GRAIL, where she headed Total Rewards and People Operations. Previously served as Head of Total Rewards at Jazz Pharmaceuticals during its growth to over 1,300 employees. Holds a BS in Accounting from University of Illinois.
Senior Associate who joined in 2026 after consulting for Longitude Capital and completing fellowships at Compound and Divergence Labs. Published work in leading journals on RAS inhibition and pancreatic cancer. Holds a PhD from MIT and Harvard Medical School.
Senior Analyst focusing on public equities who joined in 2024. Previously covered biotechnology at Deep Track Capital, Lynx1, Walleye Capital, and Columbia Threadneedle, and served as Investment Banking Vice President at Jefferies. Holds a PhD in Neurobiology from Caltech.
Executive Assistant who joined in 2018. Previously owned a Bar Method fitness studio and worked in production at ABC News 20/20. Holds a BA in Communications from Fordham University.
Director of IT who joined in 2023 with over 15 years of experience managing IT operations at Managed IT Service Providers and venture capital firms. Previously held roles at AllCovered as Senior Systems Engineer and Engineering Team Lead.
Vice President of Finance who joined in 2015. Spent seven years at KPMG (formerly Rothstein Kass) in audit and assurance with focus on life science venture capital funds. Holds a BA in Economics with emphasis in Accounting from UC Santa Barbara.
Senior Tax Manager and member of the Finance team who joined in 2024 from a16z. Previously held tax-related roles at GI Partners, Pattern Energy Group, and PricewaterhouseCoopers, focusing on private equity and venture capital funds. Holds an MS in Taxation from Golden Gate University.
Senior Associate who joined in 2024 with prior experience as an Investment Banking Analyst at Cowen covering medical technology and as a Private Equity Analyst at Montage Partners. Holds degrees in Accounting and Finance from Arizona State University.
Senior Associate who joined in 2024 from Morgan Stanley's Healthcare Investment Banking group, where she focused on the biopharmaceutical sector. Holds a Master's in Biology and BS in Human Biology from Stanford University.
Executive Assistant supporting the Biotechnology and Medical Technology teams who joined in 2007. Previously worked as an Executive Assistant at Pequot Ventures and Pollock Financial Group. Holds a BA in Sociology from Menlo College.
Compliance and Legal Manager who joined in 2022 after working as a Compliance Consultant at ACA Global advising SEC-registered investment advisers. Holds a JD from University of San Francisco School of Law and BA in Political Science from Marquette University.
Controller who joined in 2013 with prior experience as an Audit Associate at Moss Adams and PricewaterhouseCoopers, serving technology and life sciences companies. Holds a BS in Microbiology from San Jose State University.
Director of Operations & Facilities and member of the Finance team who joined in 2017. Previously held tax and accounting roles at Northgate Capital, ONSET Ventures, and PricewaterhouseCoopers. Holds a BA in Economics with emphasis in Accounting from UC Santa Cruz.
Investments · 1 tracked
founders shown can be your intro pathClinical-stage biotechnology company developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment.
Frequently asked questions
- What stage does Longitude Capital invest at?
- Longitude Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Longitude Capital focus on?
- Longitude Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is Longitude Capital located?
- Longitude Capital is headquartered in Menlo Park, US.
- Does Longitude Capital lead rounds?
- Longitude Capital typically participates in rounds rather than leading them.
Similar investors
Data Collective identifies and supports ambitious company founders developing technology-driven solutions. The firm focuses on companies using innovation to restore predictability in an unstable world, with demonstrated expertise across clean energy, gene therapy, sustainable agriculture, and machine learning applications in healthcare.
Google Ventures invests in innovative founders across diverse industries, focusing on companies where they can provide value across multiple stages and milestones through long-term relationships.
EQT Life Sciences, formerly LSP, is one of Europe's largest life sciences investors with 30 years of history and approximately 3.5 billion euros raised across 12 private funds. The firm invests in innovative therapeutics, medical devices, diagnostics, and healthtech companies globally, targeting investment sizes of 10-60 million EUR.
ARTIS Ventures is a venture capital firm focused on investing in frontier technologies at the intersection of biology, healthcare, AI, and data. The firm backs companies spanning therapeutics, medical devices, diagnostics, and digital health, with recognition including Forbes Midas List and CB Insights Top 100 VC designation.
F Prime Capital partners with scientific and engineering-focused founders to accelerate company growth through hands-on expertise from their team of scientists, engineers, physicians, and operators.